We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

Results: 3

1.
Figure 2

Figure 2. From: Mutational Profile Of Advanced Primary and Metastatic Radioactive Iodine-Refractory Thyroid Cancers Reveals Distinct Pathogenetic Roles for BRAF, PIK3CA and AKT1.

A. Mutational frequency of BRAF, RET/PTC, NRAS, HRAS, KRAS, AKT1, PIK3CA in (A) 18 primary ATC, (B) 34 primary PDTC and (C) 23 RAIR FDG-PET positive PDTC. RAS is significant more prevalent than BRAF in primary PDTC (p=0.002) and BRAF is more prevalent than RAS in RAIR PET positive PDTC (p=0.04). RET/PTC rearrangements were analyzed in cases that were wild-type for BRAF and RAS.

Julio C. Ricarte-Filho, et al. Cancer Res. ;69(11):4885-4893.
2.
Figure 1

Figure 1. From: Mutational Profile Of Advanced Primary and Metastatic Radioactive Iodine-Refractory Thyroid Cancers Reveals Distinct Pathogenetic Roles for BRAF, PIK3CA and AKT1.

Mass spectrometry (left panel) and Sanger sequencing (right panel) traces of representative samples with NRAS, AKT1 and PIK3CA mutations. Note that NRAS mutant and wild-type peaks are of comparable size, which is also reflected in the sequencing trace. By contrast, the mutant peaks in AKT1 and PIK3CA were small, and missed by Sanger sequencing. Subcloning and sequencing detected 8 of 27 (29%) and 2 of 24 (8%) clones to be mutated for AKT1 and PIK3CA, respectively. wt, wild type; mut, mutant; UEP, unextended primer.

Julio C. Ricarte-Filho, et al. Cancer Res. ;69(11):4885-4893.
3.
Figure 3

Figure 3. From: Mutational Profile Of Advanced Primary and Metastatic Radioactive Iodine-Refractory Thyroid Cancers Reveals Distinct Pathogenetic Roles for BRAF, PIK3CA and AKT1.

Genotype of multiple tumor sites in a patient with radioactive iodine refractory, FDG-PET positive thyroid carcinoma. A: Histology of primary tumor showing a papillary thyroid carcinoma (PTC), tall cell variant (TCV). B: Histology of metastatic TCV-PTC to lung 15 months after diagnosis C: Histology of metastatic TCV-PTC to right supraclavicular lymph node that developed 10 years after removal of primary tumor. This high power view shows the tumor cells (arrow) to be tall (their height at least twice their width) with strong eosinophilic cytoplasm. D, E, F: Mass spectrometry traces for BRAF mutation from primary tumor (A), first (B) and second (C) recurrence, respectively. Note the mutant BRAF_T1799A peak (arrow). G: FDG-PET scan from the second recurrence showing PET positive lesion (arrow) in the right supraclavicular area corresponding to specimen C.

Julio C. Ricarte-Filho, et al. Cancer Res. ;69(11):4885-4893.

Supplemental Content

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Write to the Help Desk